{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-010954","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.284470+00:00","generated_at":"2026-06-06T07:41:33.629571+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024","bullets":["Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.","David receives $650K base salary, 50% target bonus, $135K signing bonus, and 300K RSUs (half time-vesting, half performance-vesting).","Performance RSUs vest based on 90-day average stock price from $20 to $60+ over 5 years.","Interim CFO Richard Johnson will stay in advisory role for smooth transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-010954","json":"https://secwatch.observer/filing/0001104659-24-010954.json","markdown":"https://secwatch.observer/filing/0001104659-24-010954.md","text":"https://secwatch.observer/filing/0001104659-24-010954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/tm245238d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:41:33.629571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29a2ba7784","claim":"Glenn C. David was appointed as Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e77d3c3ffc","claim":"Richard Johnson changed role as interim Chief Financial Officer at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465924010954/0001104659-24-010954-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down as interim CFO"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}